AU2010295412A1 - Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid - Google Patents

Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid Download PDF

Info

Publication number
AU2010295412A1
AU2010295412A1 AU2010295412A AU2010295412A AU2010295412A1 AU 2010295412 A1 AU2010295412 A1 AU 2010295412A1 AU 2010295412 A AU2010295412 A AU 2010295412A AU 2010295412 A AU2010295412 A AU 2010295412A AU 2010295412 A1 AU2010295412 A1 AU 2010295412A1
Authority
AU
Australia
Prior art keywords
fucoxanthin
synergistic combination
activating
seed oil
punicic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010295412A
Other languages
English (en)
Inventor
Vladimir Badmaev
Paul M. Flowerman
Miguel Jimenez Del Rio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polifenoles Naturales SL
Original Assignee
Polifenoles Naturales SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifenoles Naturales SL filed Critical Polifenoles Naturales SL
Publication of AU2010295412A1 publication Critical patent/AU2010295412A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010295412A 2009-09-18 2010-09-17 Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid Abandoned AU2010295412A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24382809P 2009-09-18 2009-09-18
US61/243,828 2009-09-18
PCT/US2010/049364 WO2011035179A1 (en) 2009-09-18 2010-09-17 Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid

Publications (1)

Publication Number Publication Date
AU2010295412A1 true AU2010295412A1 (en) 2012-05-03

Family

ID=43086192

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010295412A Abandoned AU2010295412A1 (en) 2009-09-18 2010-09-17 Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid

Country Status (6)

Country Link
US (1) US20110070258A1 (ko)
EP (1) EP2477620A1 (ko)
KR (1) KR20120081605A (ko)
CN (1) CN102630161A (ko)
AU (1) AU2010295412A1 (ko)
WO (1) WO2011035179A1 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
WO2013019125A2 (en) * 2011-08-04 2013-02-07 Webster Judith Marie A beverage processor
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
CN102641312B (zh) * 2012-05-21 2013-10-30 新疆医科大学 石榴花多酚在制备治疗非酒精性脂肪肝的药物中的用途
BR112015010947A2 (pt) 2012-11-13 2018-06-05 Nusirt Sciences Inc composições e métodos para aumentar o metabolismo energético.
BR112015023310A2 (pt) 2013-03-15 2017-07-18 Nusirt Sciences Inc composições, métodos e kits para redução de níveis lipídicos
US9125843B2 (en) 2013-10-03 2015-09-08 Elc Management Llc Methods and compositions for improving the appearance of skin
WO2015131152A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
JP5666053B1 (ja) 2014-08-01 2015-02-12 株式会社 資生堂 長寿遺伝子発現増強剤
US9750682B2 (en) 2015-07-30 2017-09-05 Elc Management, Llc Methods and compositions for improving the appearance of skin
TWI615141B (zh) * 2016-06-23 2018-02-21 中國醫藥大學 α-桐油酸抗老化之用途
CN106983777A (zh) * 2017-04-21 2017-07-28 上海衡志贸易有限公司 褐藻石榴籽营养品及其制备方法
CN110878294B (zh) * 2018-09-05 2024-01-02 广州弘润生物科技有限公司 一种改善线粒体功能的粘红酵母去乙酰化酶蛋白4的应用
AR114010A1 (es) * 2018-10-17 2020-07-08 Team Foods Colombia Sa Composición lipídica con micronutrientes para la prevención y/o el tratamiento de enfermedades metabólicas
CN112804996A (zh) * 2019-03-05 2021-05-14 加特治疗有限公司 类胡萝卜素在衰老相关疾病的治疗中的用途
EP3705109A1 (en) * 2019-03-05 2020-09-09 Greenaltech, S.L. Carotenoids in the treatment of senescence-related diseases
CN115715804A (zh) * 2019-03-05 2023-02-28 阿尔加克蒂夫有限公司 类胡萝卜素在衰老相关疾病的治疗中的用途
IT202000017908A1 (it) 2020-07-23 2022-01-23 Univ Politecnica Delle Marche Procedimento di estrazione per ottenere una miscela di principi attivi da semi di melagrana

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367072B2 (en) * 2006-12-08 2013-02-05 Polifenoles Naturales, S.L. Composition for treating obesity and method of using the same
US20080233209A1 (en) * 2007-03-22 2008-09-25 Polifenoles Naturales, Sl Composition and method of use for the treatment of metabolic syndrome and inflammation

Also Published As

Publication number Publication date
WO2011035179A1 (en) 2011-03-24
CN102630161A (zh) 2012-08-08
KR20120081605A (ko) 2012-07-19
EP2477620A1 (en) 2012-07-25
US20110070258A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
US20110070258A1 (en) Method of slowing the aging process by activating sirtuin enzymes
Banez et al. A systemic review on the antioxidant and anti-inflammatory effects of resveratrol, curcumin, and dietary nitric oxide supplementation on human cardiovascular health
Hsu et al. Anti-inflammatory and antioxidant effects of sesame oil on atherosclerosis: a descriptive literature review
Yuzefovych et al. Different effects of oleate vs. palmitate on mitochondrial function, apoptosis, and insulin signaling in L6 skeletal muscle cells: role of oxidative stress
Derosa et al. State of the art papers Dietary and nutraceutical approach to type 2 diabetes
Potenza et al. The metabolic syndrome: definition, global impact, and pathophysiology
Reiter et al. Anti-inflammatory properties of α-and γ-tocopherol
Thomas et al. Foods for the prevention of diabetes: how do they work?
Gill et al. The role of diet and gut microbiota in regulating gastrointestinal and inflammatory disease
Isharwal et al. Diet & insulin resistance: a review & Asian Indian perspective
Liou et al. Maslinic acid protects against obesity-induced nonalcoholic fatty liver disease in mice through regulation of the Sirt1/AMPK signaling pathway
US8367072B2 (en) Composition for treating obesity and method of using the same
Kones Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition
MacRedmond et al. Conjugated linoleic acid improves airway hyper‐reactivity in overweight mild asthmatics
Nd Non-alcoholic fatty liver disease, an overview
Negro et al. Effects of 12 weeks of essential amino acids (EAA)-based multi-ingredient nutritional supplementation on muscle mass, muscle strength, muscle power and fatigue in healthy elderly subjects: a randomized controlled double-blind study
Verpeut et al. Citrus aurantium and Rhodiola rosea in combination reduce visceral white adipose tissue and increase hypothalamic norepinephrine in a rat model of diet-induced obesity
Arai et al. Effects of a palatinose-based liquid diet (Inslow) on glycemic control and the second-meal effect in healthy men
US20080233209A1 (en) Composition and method of use for the treatment of metabolic syndrome and inflammation
Sumiyoshi et al. Effects of Eleutherococcus senticosus cortex on recovery from the forced swimming test and fatty acid β-oxidation in the liver and skeletal muscle of mice
Rizzo et al. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
Choi et al. Natural bioactive compounds as potential browning agents in white adipose tissue
Qu et al. Natural products and skeletal muscle health
Akter et al. Dietary carbohydrates: Pathogenesis and potential therapeutic targets to obesity‐associated metabolic syndrome
Hou et al. Comparison and recommendation of dietary patterns based on nutrients for Eastern and Western patients with inflammatory bowel disease

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application